Gareth Gregory

View Scopus Profile

Research activity per year

If you made any changes in Pure these will be visible here soon.

Education/Academic qualification

Cancer Therapeutics, Doctor of Philosophy, University of Melbourne

Award Date: 27 May 2017

External positions

Clinical & Laboratory Haematologist, Monash Health

2013 → …

1 Finished
2 Not started
14 Active

PCNSL: Phase II study of pembrolizumab checkpoint blockade following chemoimmunotherapy for primary central nervous system lymphoma: BLOCK CNS Lymphoma
Gregory, G.
22/11/21 → 31/12/26
Project: Research
A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL)
Gregory, G.
9/08/21 → 8/08/26
Project: Research
A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab in Combination with Other Agents in Subjects with B-cell Non-Hodgkin Lymphoma
Gregory, G.
3/06/21 → 2/06/26
Project: Research
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Acalabrutinib in Combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Subjects ≤65 Years with Previously Untreated Non-Germinal Center Diffuse Large B-Cell Lymphoma
Gregory, G.
4/03/21 → 3/03/26
Project: Research
A Phase 1/2, Open-Label, Dose-Escalation Trial of GEN3013 in Patients with Relapsed, Progressive or Refractory B-Cell Lymphoma
Gregory, G.
21/08/20 → 20/08/25
Project: Research

26 Article
9 Letter
4 Poster
3 Meeting Abstract
More

A phase III trial evaluating glofitamab in combination with gemcitabine plus oxaliplatin versus rituximab in combination with gemcitabine and oxaliplatin in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL)
Hertzberg, M. S., Ku, M., Catalani, O., Althaus, B., Simko, S. & Gregory, G. P., 28 May 2021, In: Journal of Clinical Oncology. 39, 15 suppl, 1 p., TPS7575.
Research output: Contribution to journal › Meeting Abstract › Other › peer-review

Open Access
A phase III trial of glofitamab plus gemcitabine and oxaliplatin (gemox) vs rituximab plus gemox for relapsed/refractory diffuse large B-cell lymphoma
Hertzberg, M. S., Ku, M., Catalani, O., Althaus, B., Simko, S. & Gregory, G. P., Jun 2021, In: Hematological Oncology. 39, Supp 2, p. 344-345 2 p., 253.
Research output: Contribution to journal › Meeting Abstract › Other › peer-review
Bispecific antibodies: A review of development, clinical efficacy and toxicity in B-cell lymphomas
Salvaris, R., Ong, J. & Gregory, G. P., May 2021, In: Journal of Personalized Medicine. 11, 5, 15 p., 355.
Research output: Contribution to journal › Article › Research › peer-review

Open Access

4 Citations (Scopus)
Clinical illness with viable SARS-CoV-2 virus presenting 72 days after infection in an immunocompromised patient
Hughes, C. M., Gregory, G. P., Pierce, A. B., Druce, J. D., Catton, M., Chong, B., Sherry, N. L., Graham, M., Chen, M., Salvaris, R., Eise, N., Lee, J. Y. H., McQuilten, Z., Crouch, S., Looker, C., Korman, T. M. & Stuart, R. L., 2021, (Accepted/In press) In: Infection Control & Hospital Epidemiology. 3 p.
Research output: Contribution to journal › Letter › Research › peer-review

Open Access

1 Citation (Scopus)
COVID-19 vaccination in haematology patients: an Australian and New Zealand consensus position statement
McCaughan, G., Di Ciaccio, P., Ananda-Rajah, M., Gilroy, N., MacIntyre, R., Teh, B., Weinkove, R., Curnow, J., Szer, J., Enjeti, A. K., Ross, D. M., Mulligan, S., Trotman, J., Dickinson, M., Quach, H., Choi, P., Polizzotto, M. N., Tam, C. S., Ho, P. J., Ku, M. & 15 others, Gregory, G., Gangatharan, S., Hapgood, G., Cochrane, T., Cheah, C., Gibbs, S., Wei, A., Johnston, A., Greenwood, M., Prince, H. M., Latimer, M., Berkahn, L., Wight, J., Armytage, T. & Hamad, N., May 2021, In: Internal Medicine Journal. 51, 5, p. 763-768 6 p.
Research output: Contribution to journal › Article › Other › peer-review

Open Access

4 Citations (Scopus)

Albert Baikie Memorial Medal for best presentation by a new investigator at the HSANZ Annual Scientific Meeting
Gregory, Gareth (Recipient), 2014
Prize: Prize (including medals and awards)
Cancer Therapeutics CRC PhD Top Up Scholarship
Gregory, Gareth (Recipient), 2015
Prize: Competitive Fellowships
European Hematology Association Clinical Research Training in Hematology Fellowship
Gregory, Gareth (Recipient), 2017
Prize: Prize (including medals and awards)
Leukaemia Foundation PhD Scholarship
Gregory, Gareth (Recipient), 2013
Prize: Competitive Fellowships
NHMRC Medical Postgraduate Research Scholarship
Gregory, Gareth (Recipient), 2013
Prize: Competitive Fellowships

3 Contribution to conference
1 Professional association or peak discipline body

HSANZ Annual Scientific Meeting
Gareth Gregory (Session chair)
2016
Activity: Participating in or organising an event types › Contribution to conference
High-grade NHL & Hodgkin Lymphoma Disease Group Committee Member of the Scientific Advisory Committee
Gareth Gregory (Member)
2015 → 2017
Activity: External Academic Engagement › Professional association or peak discipline body
HSANZ Annual Scientific Meeting
Gareth Gregory (Speaker)
21 Oct 2014
Activity: Participating in or organising an event types › Contribution to conference
HSANZ Annual Scientific Meeting
Gareth Gregory (Speaker)
29 Oct 2012
Activity: Participating in or organising an event types › Contribution to conference

Gareth Gregory

Personal profile

Education/Academic qualification

External positions

Network

Dive into details

PCNSL: Phase II study of pembrolizumab checkpoint blockade following chemoimmunotherapy for primary central nervous system lymphoma: BLOCK CNS Lymphoma

A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab in Combination with Other Agents in Subjects with B-cell Non-Hodgkin Lymphoma

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Acalabrutinib in Combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Subjects ≤65 Years with Previously Untreated Non-Germinal Center Diffuse Large B-Cell Lymphoma

A Phase 1/2, Open-Label, Dose-Escalation Trial of GEN3013 in Patients with Relapsed, Progressive or Refractory B-Cell Lymphoma

A phase III trial evaluating glofitamab in combination with gemcitabine plus oxaliplatin versus rituximab in combination with gemcitabine and oxaliplatin in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL)

A phase III trial of glofitamab plus gemcitabine and oxaliplatin (gemox) vs rituximab plus gemox for relapsed/refractory diffuse large B-cell lymphoma

Bispecific antibodies: A review of development, clinical efficacy and toxicity in B-cell lymphomas

Clinical illness with viable SARS-CoV-2 virus presenting 72 days after infection in an immunocompromised patient

COVID-19 vaccination in haematology patients: an Australian and New Zealand consensus position statement

Albert Baikie Memorial Medal for best presentation by a new investigator at the HSANZ Annual Scientific Meeting

Cancer Therapeutics CRC PhD Top Up Scholarship

European Hematology Association Clinical Research Training in Hematology Fellowship

Leukaemia Foundation PhD Scholarship

NHMRC Medical Postgraduate Research Scholarship

HSANZ Annual Scientific Meeting

High-grade NHL & Hodgkin Lymphoma Disease Group Committee Member of the Scientific Advisory Committee

HSANZ Annual Scientific Meeting

HSANZ Annual Scientific Meeting

Gareth Gregory

Personal profile

Education/Academic qualification

External positions

Network

Projects

Research output

Prizes

Activities